Outlook Therapeutics (OTLK) Share-based Compensation Growth (3y) (2018 - 2026)
Outlook Therapeutics (OTLK) Share-based Compensation Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.49% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.55% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 7.39% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30.98% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | -16.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.15% |
| Dec 31, 2025 | -14.15% |
| Sep 30, 2025 | 9.78% |
| Jun 30, 2025 | 6.90% |
| Mar 31, 2025 | -23.21% |
| Dec 31, 2024 | 45.02% |
| Sep 30, 2024 | 0.03% |
| Jun 30, 2024 | 5.23% |
| Mar 31, 2024 | 5.07% |
| Dec 31, 2023 | 3.30% |
| Sep 30, 2023 | 20.98% |
| Jun 30, 2023 | 0.56% |
| Mar 31, 2023 | 65.62% |
| Dec 31, 2022 | 57.05% |
| Sep 30, 2022 | 88.77% |
| Jun 30, 2022 | 257.66% |
| Mar 31, 2022 | 141.32% |
| Dec 31, 2021 | 11.34% |
| Sep 30, 2021 | 75.35% |
| Jun 30, 2021 | 72.34% |